EDIT biotech catalysts & pipeline

EDITAS MEDICINE INC · Data as of 2026-10-25

Upcoming catalysts

in vivo gene editing medicines targeting HSCs — Initial data

Late 2026

We will select the lead development candidate to advance towards human proof-of-concept in September 2025 and are on track to submit an investigational new drug application by mid-2026 and achieve human proof-of-concept by year-end 2026.

Source filing

lead program — Initial data

Late 2026

Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026

Source filing

EDIT-401 — Interim data

Q1 2027

We look forward to our continued progress and expect to provide a data update in the first quarter of 2027.

Source filing

EDIT-401 — Topline data

2027

The Company plans to complete enrollment in Part 1, the dose-finding portion of the Phase 1/2 trial of EDIT-401, with topline safety and efficacy data results available later in 2027.

Source filing

EDIT-401 — Conference presentation

Nov 8

Editas will present new preclinical data demonstrating the durability of EDIT-401, supporting its potential as a transformative therapy for people living with hyperlipidemia, at the AHA Scientific Sessions on Sunday, November 8.

Source filing

Explore the free biotech catalyst calendar